Jazz Pharmaceuticals plc (JAZZ) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $229.00, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xywav (41.0%); Concentration risk — Supplier: ESSDS central pharmacy.
Jazz Pharmaceuticals is a global biopharma focused on rare diseases, with key products in sleep disorders (Xywav, Xyrem), epilepsy (Epidiolex), and oncology (Rylaze, Zepzelca, Ziihera, Modeyso). Revenue comes from pharmaceutical product sales globally, with Xywav at 41%,... Read more
Hold if already holding. Not a fresh buy at $229.00, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xywav (41.0%); Concentration risk — Supplier: ESSDS central pharmacy. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst cluster(6), earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — Jazz Pharmaceuticals plc
Latest news
- NEWS M&T Bank Corp Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat — MarketBeat neutral
- NEWS Pictet Asset Management Holding SA Sells 33,547 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat — MarketBeat neutral
- NEWS Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Oncology Data, Cannabis Shift And Modeyso Royalty News - Sahm — Sahm neutral
- NEWS NBC5 In Depth: Curator of Burlington Discover Jazz Festival shares vision - WPTZ — WPTZ neutral
- NEWS How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXywav41%10-K Item 1: 'In 2025, net product sales of Xywav were $1,657.0 million, which represented 41% of our total net product sales for the year.'
- MEDIUMProductEpidiolex26%10-K Item 1: 'Net product sales of Epidiolex/Epidyolex in 2025 were $1,059.2 million, which represented 26% of our total net product sales for the year.'
- LOWProductRylaze10%10-K Item 1: 'In 2025, net product sales of Rylaze were $402.9 million, which represented 10% of our total net product sales for the year.'
- HIGHSupplierESSDS central pharmacy10-K Item 1: 'Since 2002, we have had exclusive agreements with ESSDS, the central pharmacy for Xywav and Xyrem, to distribute Xywav and Xyrem in the U.S.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $229.00, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xywav (41.0%); Concentration risk — Supplier: ESSDS central pharmacy. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $238.45 (+4.1%), stop $217.50 (−5.3%), A.R:R -0.0:1. Score 6.1/10, moderate confidence.
Take-profit target: $238.45 (+3.4% upside). Target $238.45 (+4.1%), stop $217.50 (−5.3%), A.R:R -0.0:1. Stop-loss: $217.50.
Concentration risk — Product: Xywav (41.0%); Concentration risk — Supplier: ESSDS central pharmacy; Analyst target reached - limited upside remaining.
Jazz Pharmaceuticals plc trades at a P/E of 1921.3 (forward 9.0). TrendMatrix value score: 7.1/10. Verdict: Hold.
25 analysts cover JAZZ with a consensus score of 4.2/5. Average price target: $256.
What does Jazz Pharmaceuticals plc do?Jazz Pharmaceuticals is a global biopharma focused on rare diseases, with key products in sleep disorders (Xywav,...
Jazz Pharmaceuticals is a global biopharma focused on rare diseases, with key products in sleep disorders (Xywav, Xyrem), epilepsy (Epidiolex), and oncology (Rylaze, Zepzelca, Ziihera, Modeyso). Revenue comes from pharmaceutical product sales globally, with Xywav at 41%, Epidiolex at 26%, Rylaze at 10%, and Zepzelca at 8% of 2025 net product sales. Xywav and Xyrem are distributed exclusively through ESSDS under a REMS program.